ALAS1 and myelodysplastic syndrome: Therefore, we prepared CD34+ BM cells from four SF3B1-mutated MDS-RS patients (MDS1, TP1; MDS2, TP1; MDS3; MDS4) and one congenital sideroblastic anaemia patient (MDS5 with ALAS1 mutation), which was used as a control.